小切口有限内固定结合外固定架治疗胫腓骨骨折

胫腓骨骨折在长管状骨骨折中是较为常见的一种，胫骨全长的内侧1／3面仅位于皮下而无肌肉组织保护，骨折易成为开放性，污染常较严重。对胫腓骨骨折的治疗有多种方法，我科自1998年至2005年5月对324例胫腓骨骨折中的86例应用小切口有限内固定结合外固定支架固定取得满意疗效，现报告如下。     

下颌骨髁状突骨折的CT诊断

通过对比下颌骨髁状突骨折患者的普通Ｘ线和ＣＴ检查结果，着重提出ＣＴ诊断下颌骨髁状突骨折的方法及重要意义。     

颈椎骨折类型与脊髓损伤关系之临床观察

通过对９２例颈椎骨折病例的分析，发现屈曲型损伤最多见（５３％），其次为过伸型（２６％），压缩型（２１％）。屈曲型和压缩型多见于年轻人，而屈曲损伤导致的脱位及过伸型则多见于年龄较大者。爆裂骨折引起的神经损害最重，其次为屈曲型、过伸型及压缩（非爆裂）骨折。神经功能改善率以爆裂型骨折最差，死亡率亦最高，以压缩（非爆裂型）骨折最好，其次为过伸型及屈曲型。文内对各型的特点进行了详细讨论。     

神经肽P物质对肉芽组织成纤维细胞增殖及表皮生长因子基因表达的作用

目的：探讨感觉神经肽P物质（SP）对离体培养的肉芽组织成纤维细胞的促增殖作用及其对表皮生长因子（EGF）基因表达的调控作用。方法：采用MTT法测定SP对肉芽组织成纤维细胞的促增殖作用；采用逆转录－聚合酶链反应（RT－PCR）方法检测SP对成纤维细胞EGF基因表达的调控作用，观察时间及剂量－效应关系。结果：10^-9～10^-5mol/L的SP在体外对肉芽组织成纤维细胞均具有明显的促增殖作用（P＜0．01），且具有明显的剂量依赖性（γ=0.594,P＜0．01），EGF抗体只能部分抑制这一作用（与对照组比较，P＜0．01；与10^-7mol/L SP组比较，P＜0．05）。10^-7mol/L SP可诱导成纤维细胞EGF mRNA的表达，在作用后6h与对照组比较，差异有非常显著性意义（P＜0．01）；SP在10^-8～10^-6mol/L范围内可以显著促进成纤维细胞EGF mRNA表达，在10^-7mol/L达到峰值，当浓度＞10^-7mol/L时，其促EGF mRNA表达的效应强度随浓度升高而有所降低，至10^-5mol/L时与对照组比较，差异无显著性意义。结论：SP对肉芽组织成纤维细胞具有明显的促增殖作用，这种作用与其诱导成纤维细胞EGF表达有关。     

手术治疗外展外旋力所致踝关节骨折

手术治疗外展外旋力引起的踝关节骨折３５例，平均随访２年半，满意率为８８．６％。效果不佳者与软组织损伤严重和关节软骨受损有关。恢复腓骨的长度对防止距骨移位与倾斜十分重要。用钢板固定外踝时要使其下端适应腓骨下段的外翻角。下胫腓联合不论是完全还是不全分离，都应用螺钉固定，以增加踝关节稳定性，早期练习活动。三角韧带断裂时，只要腓骨解剖复位与坚强固定，三角韧带可不予修复。对小于胫骨远端关节面２５％的后踝骨折可不予处理。     

肱骨外髁骨折165例病案分析

总结分析了165例肱骨外髁骨折。初诊时,漏诊12例,误诊91例,闭合复位失败55例。按骨折不同类型和软组织损伤情况分别从七个方面:1.无移位骨折,2.移位或翻转移位骨折,3.软组织嵌入闭合复位困难,4.局部严重肿胀,5.陈旧性骨折,6.骨折畸形愈合并发肘外(内)翻严重,7.并发肘关节僵硬,提示了不同的治疗方法。介绍了手术时如何辨认骨折面、清除疤痕组织和骨痂、松解粘连的力法,以及1枚克氏针加粗丝线内固定法的操作要点。     

重组人表皮生长因子对促进Ⅱ度烧伤愈合的作用

目的 探讨重组人表皮生长因子(rhEGF)对促进Ⅱ度烧伤创面愈合的作用。方法 采用自身对照研究方法,选取46例Ⅱ度烧伤患者观察最适治疗浓度创面局部应用的治疗效果及不良反应。结果 在浅Ⅱ度烧伤创面,观察组的愈合时间为(8.7±2.1)天,对照组为(12.2±2.4)天,而深Ⅱ度烧伤创面观察组的愈合时间是(13.4±2.6)天,对照组为(19.2±3.2)天。与对照组相比,观察组创面愈合时间均有明显缩短(P<0.01),结论 rhEGF对Ⅱ度烧伤创面均可有效地促进组织修复,加快创面愈合速度,有良好的促进愈合作用,而药物反应极轻微。     

烧伤研究与治疗进展

对近年来国外烧伤研究及治疗进展作一综述     

Incisional healing in rats treated with diethyl maleate

Diethyl maleate (DEM) which binds and thus depletes tissue glutathione levels was used to aggravate the injury and to determine its effect on incisional healing. A 5 cm dorsal midline skin incision was performed on 40 albino Wistar rats in two groups and then closed by interrupted sutures. Groups received 0.9% NaCl and DEM at a dosage of 1 mg/kg/day intraperitoneally for seven days, respectively. On postoperative days 7 and 14, histopathological assessment and tensile strengths were measured. The DEM treated group had a marked inflammation with poorly defined collagen formation and the tensile strength measurements revealed a significant decrease (p <0.001) on the 7t day. On the other hand, the first group showed better collagenization and a lesser degree of inflammation. However, on the 14th day, there was no noticeable histopathological difference between the two groups; but, tensile strength values of the second group were still lower (p <0.05). In this animal model, DEM postponed the healing process and reduced the tensile strength.     

Randomized clinical trial of ascorbic acid in the treatment of pressure ulcers

The objective of this study was to assess the effects of ascorbic acid supplementation, 500 mg twice daily in the treatment of pressure ulcers as an adjunct to standardized treatment.

The design consisted of a multicenter blinded randomized trial. The control group received 10 mg of ascorbic acid twice daily.

Patients from 11 nursing homes and 1 hospital participated.

Main outcome measures included wound survival, healing rates of wound surfaces, and clinimetric changes over 12 weeks.

Eighty-eight patients were randomized. Intention-to-treat analysis showed that the wound closure probability per unit time (i.e., the closure rate) was not higher in the intervention group than in the control group (Cox hazard ratio of 0.78 [90% precision interval, 0.44–1.39]). Mean absolute healing rates were 0.21 and 0.27 cm²/week in the intervention and control group, respectively (PI of the adjusted difference: −0.17 to 0.13). Relative healing rates and healing velocities did not show favorable results of ascorbic acid supplementation, either. A panel scored slides of the ulcers with a report mark between 1 (bad) and 10 (excellent). The improvement was 0.45 and 0.72 points per week in the intervention and control group, respectively (PI of the adjusted difference: −0.50 to 0.20). With another clinimetric index we could not show any differences, either.

These data do not support the idea that ascorbic acid supplementation (500 vs. 10 mg twice daily) speeds up the healing of pressure ulcers.